Amneal Pharmaceuticals (NASDAQ:AMRX) Releases FY 2026 Earnings Guidance

Amneal Pharmaceuticals (NASDAQ:AMRX) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 0.930-1.030 for the period, compared to the consensus EPS estimate of 0.920. The company issued revenue guidance of $3.1 billion-$3.2 billion, compared to the consensus revenue estimate of $3.2 billion.

Amneal Pharmaceuticals Price Performance

Shares of Amneal Pharmaceuticals stock opened at $13.81 on Friday. The business has a fifty day simple moving average of $13.74 and a two-hundred day simple moving average of $11.74. Amneal Pharmaceuticals has a 1 year low of $6.68 and a 1 year high of $15.42. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 60.05 and a beta of 1.36.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Truist Financial set a $15.00 price target on shares of Amneal Pharmaceuticals in a research note on Wednesday, January 7th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Amneal Pharmaceuticals in a research report on Wednesday, January 21st. Finally, Barclays started coverage on Amneal Pharmaceuticals in a report on Monday, December 8th. They set an “overweight” rating and a $15.00 price target for the company. Four investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $13.80.

More Amneal Pharmaceuticals News

Here are the key news stories impacting Amneal Pharmaceuticals this week:

• Positive Sentiment: Q4 and full‑year results showed clear improvement: Q4 adjusted EPS of $0.21 beat consensus and Q4 revenue was $814M; full‑year 2025 revenue rose to $3.02B with GAAP net income of $72M and adjusted EBITDA growth. These results underline recovering profitability and stronger specialty sales. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Company issued 2026 adjusted diluted EPS guidance of $0.93–$1.03 (above the cited consensus ~$0.92), signaling management confidence in continued margin and earnings improvement. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Growth drivers: Specialty products (CREXONT®, UNITHROID®, new branded launches such as BREKIYA®) and AvKARE distribution gains are cited by management as the primary growth engines — supportive long‑term but timing/launch execution will matter. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Neutral Sentiment: Analyst/institution activity: recent coverage includes overweight views and price targets around the mid‑teens; institutional flows are mixed per data aggregators — watch for any analyst reactions to the new guidance. QuiverQuant Summary
• Negative Sentiment: Revenue guidance is effectively in a narrow band (~$3.05–$3.15B per the press release; another bulletin cited $3.10–$3.20B), which is around or a touch below some Street revenue expectations — investors may mark the stock down on any perception of decelerating top‑line growth. Amneal Reports Fourth Quarter and Full Year 2025 Financial Results
• Negative Sentiment: Leverage remains a material risk: gross debt increased after refinancing and net debt was reported near ~$2.4B with net leverage around ~3.5x on 2025 adjusted EBITDA — higher interest/credit risks could cap valuation until deleveraging progresses. QuiverQuant Summary
• Negative Sentiment: Short‑interest data is noisy and recently volatile in third‑party feeds (one snapshot shows ~10.6M shares short, ~4.1% of float); elevated short positions and data inconsistencies can amplify intraday moves and volatility. MarketBeat AMRX page

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Comerica Bank lifted its holdings in Amneal Pharmaceuticals by 186.7% in the third quarter. Comerica Bank now owns 3,005 shares of the company’s stock valued at $30,000 after buying an additional 1,957 shares during the period. Kemnay Advisory Services Inc. acquired a new position in Amneal Pharmaceuticals during the fourth quarter worth $26,000. Federated Hermes Inc. raised its holdings in shares of Amneal Pharmaceuticals by 1,680.6% in the 4th quarter. Federated Hermes Inc. now owns 2,297 shares of the company’s stock worth $29,000 after acquiring an additional 2,168 shares during the last quarter. Cerity Partners LLC grew its holdings in Amneal Pharmaceuticals by 19.1% during the fourth quarter. Cerity Partners LLC now owns 14,443 shares of the company’s stock worth $182,000 after buying an additional 2,318 shares in the last quarter. Finally, Transamerica Financial Advisors LLC lifted its position in shares of Amneal Pharmaceuticals by 541.9% during the fourth quarter. Transamerica Financial Advisors LLC now owns 2,914 shares of the company’s stock valued at $37,000 after purchasing an additional 2,460 shares in the last quarter. 31.82% of the stock is owned by institutional investors and hedge funds.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a publicly traded integrated healthcare company specializing in the development, manufacturing and distribution of generic and specialty pharmaceutical products. The company’s portfolio includes oral solids, injectables, transdermals and biosimilars, serving a broad range of therapeutic areas such as cardiovascular, neuroscience, oncology and women’s health. Alongside its generic offerings, Amneal has built a branded portfolio through strategic acquisitions and internal development, positioning itself across both high-volume generics and higher-value specialty treatments.

Since its founding in 2002 by brothers Chirag and Chintu Modgil, Amneal has pursued growth through organic investment in research and development as well as targeted M&A.